New Developments Show a Promising Future for Ovarian Cancer Treatments

The results from another phase III clinical trial dealing with treatment of ovarian cancer were also recently presented at the 2017 ESMO conference in Madrid. Currently, the drug Rubraca is cleared for treatment of patients with ovarian cancer and a BRCA mutation as a single therapy when the patients have already received chemotherapy. The information from the recent phase III trial indicates that Rubraca significantly improved the survival of patients of ovarian cancer without further disease progression.